Signaling pathway screening platforms are an efficient approach to identify therapeutic targets in cancers that lack known driver mutations: a case report for a cancer of unknown primary origin

Precision medicine aims to tailor cancer therapies to target specific tumor-promoting aberrations. For tumors that lack actionable drivers, which occurs frequently in the clinic, extensive molecular characterization and pre-clinical drug efficacy studies will be required. A cell line maintained at l...

Descripción completa

Detalles Bibliográficos
Autores principales: Torres-Ayuso, Pedro, Sahoo, Sudhakar, Ashton, Garry, An, Elvira, Simms, Nicole, Galvin, Melanie, Leong, Hui Sun, Frese, Kristopher K, Simpson, Kathryn, Cook, Natalie, Hughes, Andrew, Miller, Crispin J, Marais, Richard, Dive, Caroline, Krebs, Matthew G, Brognard, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010465/
https://www.ncbi.nlm.nih.gov/pubmed/29951225
http://dx.doi.org/10.1038/s41525-018-0055-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010465/
https://www.ncbi.nlm.nih.gov/pubmed/29951225
http://dx.doi.org/10.1038/s41525-018-0055-6

Ejemplares similares